Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Adynxx

Adynxx

Adynxx is a biopharmaceutical company developing pain management drugs.

Adynxx is a clinical-stage pharmaceutical company that is developing a technology platform for addressing pain at its molecular roots, treating the development of pain following a surgery or trauma and chronic pain syndromes.

Adynxx's pipeline of products includes brivoligide, a Phase 2 drug candidate that is intended to address postoperative pain, and AYX2, a pre-clinical candidate that is intended to treat chronic syndromes of pain—including inflammatory and neuropathic pain.

The company announced its merger with Alliqua BioMedicalin April 2019, with the stockholders of Adynxx to become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis. It brought on board the post-op pain drug brivoligide.

Timeline

April 22, 2019
Adynxx announces a merger agreement with Alliqua BioMedical and provides a business and clinical update.
January 10, 2017
Adynxx raises a $16,000,000 series B round.
January 11, 2011
Adynxx raises a $4,800,000 series A round.

Funding rounds

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

References

Golden logo
By using this site, you agree to our Terms & Conditions.